SURAKSHA Q1 FY27 Concall Summary & Key Takeaways (SURAKSHA)

SURAKSHA Q1 FY27 (Jun-2026 Qtr) Earnings call highlights: Key takeaways, performance, financial metrics, outlook and guidance, concerns and management tone.

  • SURAKSHA Financials
  • SURAKSHA Shareholding Pattern
  • SURAKSHA Earnings Documents
  • SURAKSHA Announcements
  • SURAKSHA Corporate Actions
  • SURAKSHA Bulk, Block & Insider Deals
  • SURAKSHA Delivery Data
  • SURAKSHA Earnings Concalls
  • Market Timeline
  • Concall Monitor
  • Company Research
  • Earnings Monitor
  • Upcoming Results
  • Sector Monitor
  • Sector Performance
  • Bulk & Block Deals
  • Delivery Data
  • FII & DII Activity
  • Market Indices
  • Plans & Pricing

Suraksha Diagnostic Ltd (SURAKSHA) Q1FY27 Concall Summary - Jun-2026 Qtr

Performance Overview

  • Suraksha Diagnostic Ltd reported a strong start to FY27, demonstrating robust year-over-year growth with a 21% increase in revenue, a 28% rise in EBITDA, and a significant 40% jump in PAT, reflecting the strength of its underlying business and strategic execution.
  • The company continued its strategic network expansion by commissioning one hub and three spoke centers in Q1, and has already added two more hubs and three spokes in the current quarter, extending its footprint beyond West Bengal into Jharkhand and soon Tripura.
  • A key highlight was the significant ramp-up of newer centers (under 2 years old), which turned profitable for the first time, achieving a 6.5% EBITDA margin, a substantial improvement from a -5.5% margin in the previous quarter.
  • The Genomics division showed exceptional growth, with revenue increasing by 136% YoY to INR 13.7 million, marking five consecutive quarters of sequential growth and positioning it as a potential future growth pillar.
  • The company is advancing its technological capabilities, notably by introducing a blood test for Alzheimer's, initiating an AI-based project for early Alzheimer's detection from brain MRIs, and acquiring a Genexus equipment for fast genome sequencing, which reduces test turnaround time from 14-17 days to just 48 hours.

Financial Metrics

Log in to Stocksigma to read the Financial Metrics section of this summary.

Operating Performance / Business Segments

Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.

Key Discussions & Insights

Log in to Stocksigma to read the Key Discussions & Insights section of this summary.

Outlook and Guidance

Log in to Stocksigma to read the Outlook and Guidance section of this summary.

Challenges / Concerns

Log in to Stocksigma to read the Challenges / Concerns section of this summary.

Industry / Competitive Landscape

Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.

Overall Summary

Log in to Stocksigma to read the Overall Summary section of this summary.

  • SURAKSHA Q1FY27 Concall Transcript
  • SURAKSHA Q1FY27 Management Mirror
  • SURAKSHA Q4FY26 Concall Summary (Mar-2026 Qtr)